Scholarlink

Background <p>Patients with head and neck squamous cell carcinoma (HNSCC) often exhibit only partial responses to immunotherapy, resulting in poor prognosis and potential overtreatment. While pseudogenes are known to significantly impact the tumor microenvironment (TME) and tumor prognosis, their specific role in HNSCC remains unclear.</p> Methods <p>A prognostic risk profile for HNSCC patients was developed and validated using pseudogene pairs. The prognostic value of the risk signiture was assessed using survival analysis, ROC analysis, and Cox regression models. Correlations between our risk profile and immunologic characteristics of the TME were analyzed, with TIDE scores used to predict immunotherapy responses. LAT, identified as a central gene in the risk model through WGCNA and Friend analysis, was further investigated. LAT expression and its association with immune cells and immune checkpoints within the TME were examined using an internal cohort and immunofluorescence.</p> Results <p>The model based on pseudogene pairs demonstrated strong prognostic power, with significantly longer overall survival in low-risk patients compared to high-risk ones. Additionally, risk scores were inversely related to immune infiltration and predictive of immunotherapy response. LAT, identified as a potential hub gene in the low-risk group, showed stable performance across multiple validation sets and was positively correlated with T cell infiltration and high expression in an inflammatory TME.</p> Conclusion <p>A pseudogene pair-based survival prediction model for HNSCC was developed and validated, providing valuable insights for HNSCC treatment. LAT may serve as a novel biomarker for predicting immune response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pseudogene pair-based prognostic model reveals LAT as a biomarker of immune response in head and neck squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月11日

查看全文
  • Qin Ding,
  • Wenquan Hong,
  • Guanghao Chen,
  • Ting Lin,
  • Xiaochuan Chen,
  • Hanxuan Yang,
  • Wenqian Xu,
  • Xinyi Hong,
  • Jinghua Lai,
  • Sufang Qiu,
  • Jun Lu

摘要

Background

Patients with head and neck squamous cell carcinoma (HNSCC) often exhibit only partial responses to immunotherapy, resulting in poor prognosis and potential overtreatment. While pseudogenes are known to significantly impact the tumor microenvironment (TME) and tumor prognosis, their specific role in HNSCC remains unclear.

Methods

A prognostic risk profile for HNSCC patients was developed and validated using pseudogene pairs. The prognostic value of the risk signiture was assessed using survival analysis, ROC analysis, and Cox regression models. Correlations between our risk profile and immunologic characteristics of the TME were analyzed, with TIDE scores used to predict immunotherapy responses. LAT, identified as a central gene in the risk model through WGCNA and Friend analysis, was further investigated. LAT expression and its association with immune cells and immune checkpoints within the TME were examined using an internal cohort and immunofluorescence.

Results

The model based on pseudogene pairs demonstrated strong prognostic power, with significantly longer overall survival in low-risk patients compared to high-risk ones. Additionally, risk scores were inversely related to immune infiltration and predictive of immunotherapy response. LAT, identified as a potential hub gene in the low-risk group, showed stable performance across multiple validation sets and was positively correlated with T cell infiltration and high expression in an inflammatory TME.

Conclusion

A pseudogene pair-based survival prediction model for HNSCC was developed and validated, providing valuable insights for HNSCC treatment. LAT may serve as a novel biomarker for predicting immune response.